PR90558

PARIS, July 12, 2021 /PRNewswire=KYODO JBN/--

Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in

RNA-targeted small molecules, announced today that they have entered into a

strategic collaboration to identify and develop RNA-modulatory drugs for the

treatment of neurological diseases.

Under the collaboration agreement, Nymirum will leverage its proprietary DART

Platform (Dynamic Atomic-Resolution RNA Targeting Platform) to discover novel

small molecule therapeutics for multiple neurological targets. Servier is

responsible for joint preclinical development and has the right to pursue

further development on the current targets as well as expand the scope of the

collaboration. The collaboration provides Nymirum with an initial payment,

followed by future success payments.

"We are excited to pair Nymirum's expertise in targeting RNA with Servier's

experience in CNS (Central Nervous System) to advance transformative therapies.

The ability to resolve and leverage RNA's dynamic structure opens a new chapter

for drug discovery, enabling novel programs across all therapeutic areas," said

Joshua Fairbank, Chief Executive Officer and Co-Founder of Nymirum. "Thanks to

its expertise in CNS and small molecule therapeutics, Servier is a valuable

partner in this collaboration, and together we look forward to accelerating the

search for treatments for patients with severe neurological disorders."

"This new collaboration is the opportunity to progress innovative RNA-targeted

approaches towards clinical assessment in patients with very limited or absent

treatment options," stated Ross Jeggo, Global Head of Neuroscience and

Immuno-inflammation Therapeutic Area at Servier. "We are delighted to work in

partnership with Nymirum on multiple drug discovery projects, harnessing their

platform to deliver RNA-targeting small molecules for neurodegenerative

diseases. The therapeutic advantage associated to a small molecule versus other

DNA- or RNA-based approaches is truly innovative and very promising for

potential treatments for patients suffering from disorders of the central

nervous system."

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a

strong international presence in 150 countries and a total revenue of 4.7

billion euros in 2020, Servier employs 22,500 people worldwide.

More information: servier.com

Follow us on Social Media:

Facebook:  

https://fr-fr.facebook.com/login/?next=https%3A%2F%2Ffr-fr.facebook.com%2FServier%2F

Twitter:   https://twitter.com/servier

LinkedIn:  https://www.linkedin.com/company/servier

About Nymirum

Nymirum's mission is to unlock the power of RNA with small molecules to enable

the advancement of transformative medicine.

More information:  https://www.nymirum.com/

PDF - https://mma.prnewswire.com/media/1561211/Servier_Nymirum.pdf

Logo - https://mma.prnewswire.com/media/1561177/Servier_Nymirum_Logo.jpg

Contact:  presse@servier.com

Source:  Servier and Nymirum